Sector News

Pharma and biotech rebound in annual trust study

May 15, 2017
Life sciences

When it comes to pharma, consumers still have trust issues. But the good news from Edelman’s 2017 Trust Barometer study is that things are improving.

Fifty-one percent of Americans now say they trust the industry, a gain of 4% year over year. Biotech saw an even bigger jump of 12% to 62% this year. Both industries had dipped by 2% in the U.S. the year prior.

But while the news is good, it isn’t great.

“What needs to be kept in mind is that four-point increase brings pharma to a score of 51 in the U.S.,” Kym White, Edelman’s global chair for the health sector, said in an interview. “Fifty-one is neutral territory though—from 50-59 is neutral or the undecided voters, while less than 50 is distrust territory. That means there is still room for significant improvement.”

Another problem? Continued unfavorable perceptions of pharma in the U.S. In new questions this year, Edelman asked people if they think pharma puts profits ahead of people—and eight in 10 said yes. Another new question about government intervention had eight in 10 people agree that the government needs to do more to regulate the pharma industry.

“Progress is being made with that four-point jump in the United States, and yet I don’t think it’s safe to say the wind is at our backs. There are still significant challenges moving forward,” White said.

The progress pharma is making is likely due to several factors. Leading the way is innovation, she said, with game-changing progress in areas like immuno-oncology, hepatitis C and rare diseases leading to increased trust from patients and consumers in general. Other reputation-burnishing initiatives from pharma include more aggressive corporate marketing campaigns, stronger leadership stances, and the spillover effect from the halo of technology, like IBM Watson pharma partnerships and the Cancer Moonshot.

“Collectively, all of these factors are coalescing to drive some of the increase we are seeing in trust. I do not believe that it is just about one thing. But having said that, minus innovation, it’s hard to imagine that trust would be moving forward at the pace in which it is,” White said.

Globally, the trust story for pharma was also mixed. Edelman collects data from 28 countries, but only 11 markets showed positive (60% or higher) trust scores, with trust declining year over year in 14 countries.

The Edelman study also looks at other industries as well as the overall healthcare industry. The news in general for healthcare—which includes hospitals and clinics, biotech, OTC, insurance and pharma as categories—was also positive. While the industry is still the second least-trusted in the U.S., healthcare gained three percentage points in 2017 with 62% of people now saying they trust it. Only financial services, at 60%, fared worse. Technology was the most trusted industry, scoring a 75% among Americans, followed by education and retail, which were tied at 73%.

Among the more general findings of the larger study across industries was that employees are now the most trusted spokespeople for a company, while CEOs hit an all-time low with only 37% of people globally ranking them as extremely or very credible, down 12% from last year.

By Beth Snyder Bulik

Source: Fierce Pharma

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]